Evidence map›Paper›PMID 17254508›Full record

ArticleCurrent infectious disease reports2007

Testing for HIV infection in the United States.

Lindsey L Wolf, Rochelle P Walensky

Abstract read
PubMed Publisher
In one paragraph

Article in Current infectious disease reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lindsey L WolfDivision of General Medicine, Massachusetts General Hospital, 50 Staniford Street, 9th Floor, Boston, MA 02114, USA.
Rochelle P Walensky

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Daniel Lingwood · 2004 to 2026
$94.4M
Development and application of a new simulation model for COVID-19R01AI042006 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Anne Neilan · 1998 to 2026
$12.9M
Evaluating the Link between HIV Prevention and TreatmentR01MH065869 · NIMH · YALE UNIVERSITY · PI PALTIEL, A. DAVID · 2002 to 2010
$5.2M
Optimizing strategies for universal HIV testingR01MH073445 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI WALENSKY, ROCHELLE P. · 2006 to 2010
$3.3M
NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI042006NIMH NIH HHS R01 MH065869NIMH NIH HHS R01 MH073445
6 · The paper itself

Abstract

The process by which HIV-infected individuals are tested and identified has changed with the evolving HIV epidemic and public health response. In this review, we discuss the rationale for increased HIV testing as well as the current standards in HIV diagnostics and their inherent limitations. Current policy guidelines for routine HIV testing from the U.S. Preventive Services Task Force and the U.S. Centers for Disease Control and Prevention are divergent. However, national momentum toward the implementation of routine HIV testing programs continues based on the efficacy and feasibility of these programs in terms of HIV case identification and on recent reports of their cost-effectiveness. As routine, voluntary HIV screening programs are established, issues surrounding consent, reporting, and stigma still persist, as does the challenge of effectively linking detected HIV cases to care.

Identifiers

PMID17254508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.